तुलना करने के लिए मीट्रिक्स | RLYB | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधRLYBपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −5.3x | −2.1x | −0.5x | |
PEG अनुपात | −0.06 | −0.04 | 0.00 | |
क़ीमत/बुक | 0.8x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 55.4x | 41.3x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | −10.9% | 101.6% | 48.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 10.9% | 6.9% | अनलॉक करें |
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.